Last reviewed · How we verify
DALFAMPRIDINE
At a glance
| Generic name | DALFAMPRIDINE |
|---|---|
| Drug class | Potassium Channel Blocker [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2010 |
Approved indications
Common side effects
- Urinary tract infection
- Insomnia
- Dizziness
- Headache
- Nausea
- Asthenia
- Back pain
- Balance disorder
- Multiple sclerosis relapse
- Paresthesia
- Nasopharyngitis
- Constipation
Key clinical trials
- Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor (PHASE1)
- 4-Aminopyridine to Treat Skin Burns (PHASE2)
- Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis (PHASE4)
- 4AP for Carpal Tunnel Syndrome (CTS) (PHASE2)
- 4-aminopyridine Treatment for Nerve Injury (PHASE2, PHASE3)
- Cross-over Study on the Influence of Fampridine on Working Memory in Mild to Moderate Depression (PHASE2)
- A Randomized, Parallel-arm, Double Blind, Placebo-controlled Study to Assess the Efficacy of Fampridine for Patients With Spinocerebellar Ataxia SCA27B Caused by a GAA Expansion in the FGF14 Gene (PHASE3)
- Firdapse for Post-BOTOX Vocal Weakness (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DALFAMPRIDINE CI brief — competitive landscape report
- DALFAMPRIDINE updates RSS · CI watch RSS